Reducing unnecessary biopsy during prostate cancer screening using a four-Kallikrein panel: An independent replication

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2493-2498

  Vickers, Andrew ^a   Cronin, Angel ^a   Roobol, Monique ^a   Savage, Caroline ^a   Peltola, Mari ^a   Pettersson, Kim ^a   Scardino, Peter T ^a   Schröder, Fritz ^a   Lilja, Hans ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; KALLIKREIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TUMOR BIOPSY; BIOPSY; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; EARLY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOPSY; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77953688557     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.1968     Document Type: Article

References (17)

1. Thompson IM, Ankerst DP, Chi C, et al: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294:66-70, 2005 (Pubitemid 41002840)
2. Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Fadare O, Wang S, Mariappan MR: Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med 128:557-560, 2004 (Pubitemid 38584562)
4. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
5. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004
6. Vickers AJ, Cronin AM, Aus G, et al: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 6:19, 2008
7. Roobol MJ, Kirkels WJ, Schroder FH: Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 92:48-54, 2003 (suppl 2) (Pubitemid 38091140)
8. Väisänen V, Peltola MT, Lilja H, et al: Intact free prostate-specific antigen and free and total human glandular kallikrein 2: Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem 78:7809-7815, 2006
9. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988
10. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26:565-574, 2006 (Pubitemid 44728772)
11. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 22:184-204, 2001 (Pubitemid 32458158)
12. Nurmikko P, Vaisanen V, Piironen T, et al: Production and characterization of novel anti-prostate- specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 46:1610-1618, 2000
13. Mikolajczyk SD, Catalona WJ, Evans CL, et al: Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50:1017-1025, 2004 (Pubitemid 38725789)
14. Deras IL, Aubin SM, Blase A, et al: PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587-1592, 2008
15. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284, 2006 (Pubitemid 43121812)
16. Vickers AJ, Cronin AM, Aus G, et al: Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated PSA: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. Cancer (in press)
17. Andriole GL, Grubb RL 3rd, Buys SS, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009